文献速递前列腺癌

核特异性AR-V7蛋白定位是指导转移性去势抵抗性前列腺癌治疗选择的必要条件

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2016-12-12

该横断面队列研究纳入161例转移性去势抵抗性前列腺癌(mCRPC)患者,于开始新一线系统治疗前采集193份血样(191份可评估),比较核特异性与核无关AR-V7评分标准与紫杉烷或雄激素受体信号抑制剂(ARSi)疗效的关系。核特异性标准阳性34份(18%),核无关标准阳性56份(29%)。核特异性AR-V7阳性与紫杉烷治疗的交互作用与总生存显著相关(HR 0.24,95%CI 0.078-0.79;p=0.019),核无关标准下该交互作用不显著。结论:使用CTC中AR-V7蛋白生物标志物可靠指导治疗选择需要核特异性定位。

要点

  • 核特异性AR-V7阳性者接受紫杉烷较ARSi的总生存交互作用显著(HR 0.24,95%CI 0.078-0.79;p=0.019)。
  • 核无关标准下该交互作用不显著,无法可靠指导治疗选择。
  • ARSi治疗后12周,核特异性阳性16份中无一份PSA缓解≥50%,核无关阳性32份中6份(19%)缓解。

核心结论

  • 使用循环肿瘤细胞中AR-V7蛋白生物标志物可靠指导治疗选择需要核特异性定位。

研究设计与样本

  • 横断面队列研究,2012年12月至2015年3月在纪念斯隆凯特琳癌症中心采集161例独特mCRPC患者开始新一线系统治疗前的193份血样,其中191份可评估。

主要发现

  • 核特异性标准阳性34份(18%),核无关标准阳性56份(29%)。
  • ARSi治疗后12周,核特异性AR-V7阳性16份中无一份PSA缓解≥50%,核无关AR-V7阳性32份中6份(19%)缓解。
  • 影响总生存的最强基线因素为核特异性AR-V7阳性循环肿瘤细胞与紫杉烷治疗的交互作用(HR 0.24,95%CI 0.078-0.79;p=0.019)。
  • 使用核无关标准时该交互作用不显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumor cells (CTCs) expressing AR-V7 protein localized to the nucleus (nuclear-specific) identify metastatic castration-resistant prostate cancer (mCRPC) patients with improved overall survival (OS) on taxane therapy relative to the androgen receptor signaling inhibitors (ARSi) abiraterone acetate, enzalutamide, and apalutamide. OBJECTIVE: To evaluate if expanding the positivity criteria to include both nuclear and cytoplasmic AR-V7 localization ("nuclear-agnostic") identifies more patients who would benefit from a taxane over an ARSi. DESIGN, SETTING, AND PARTICIPANTS: The study used a cross-sectional cohort. Between December 2012 and March 2015, 193 pretherapy blood samples, 191 of which were evaluable, were collected and processed from 161 unique mCRPC patients before starting a new line of systemic therapy for disease progression at the Memorial Sloan Kettering Cancer Center. The association between two AR-V7 scoring criteria, post-therapy prostate-specific antigen (PSA) change (PTPC) and OS following ARSi or taxane treatment, was explored. One criterion required nuclear-specific AR-V7 localization, and the other required an AR-V7 signal but was agnostic to protein localization in CTCs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Correlation of AR-V7 status to PTPC and OS was investigated. Relationships with survival were analyzed using multivariable Cox regression and log-rank analyses. RESULTS AND LIMITATIONS: A total of 34 (18%) samples were AR-V7-positive using nuclear-specific criteria, and 56 (29%) were AR-V7-positive using nuclear-agnostic criteria. Following ARSi treatment, none of the 16 nuclear-specific AR-V7-positive samples and six of the 32 (19%) nuclear-agnostic AR-V7-positive samples had ≥50% PTPC at 12 weeks. The strongest baseline factor influencing OS was the interaction between the presence of nuclear-specific AR-V7-positive CTCs and treatment with a taxane (hazard ratio 0.24, 95% confidence interval 0.078-0.79; p=0.019). This interaction was not significant when nuclear-agnostic criteria were used. CONCLUSIONS: To reliably inform treatment selection using an AR-V7 protein biomarker in CTCs, nuclear-specific localization is required. PATIENT SUMMARY: We analyzed outcomes for patients with metastatic castration-resistant prostate cancer on androgen receptor signaling inhibitors and standard chemotherapy. Patients with circulating tumor cells that had AR-V7 protein in the cellular nuclei were very likely to survive longer on taxane-based chemotherapy, and tests unable to distinguish where the protein is located in the cell are not as predictive of benefit.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016. PMID: 27979426. doi:10.1016/j.eururo.2016.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。